ライフサイエンスコーパス: alternative agent

1 and then by three months of therapy with the alternative agent.

2 nts cannot tolerate it and must switch to an alternative agent.

3 eased mortality for polymyxins compared with alternative agents.

4 t can be utilized to guide chemotherapy with alternative agents.

5 Alternative agents and approaches, including parenteral

6 been established for future trials employing alternative agents and exploration of combination therap

7 cycle of 2-CdA; 2 patients were treated with alternative agents; and 6 patients were observed.

8 ouraged in patients with glioblastoma, since alternative agents are available and a detrimental effec

9 istant to conventional treatment; therefore, alternative agents are needed.

10 tumors that are resistant to treatment, and alternative agents are needed.

11 cessary treatment and inferior outcomes with alternative agents as well as adverse public health outc

12 he present time, there are several effective alternative agents available, so transition to an altern

13 means all studies have shown advantages over alternative agents, but concerns also remain over acute

14 r-oligomerized TRAIL may be considered as an alternative agent for testing in clinical trials.

15 ion of treatment, dosing of aminoglycosides, alternative agents for gram-positive organisms, aspirin

16 nsus guidelines recommend considering use of alternative agents for infections involving a higher van

17 cline-class antimicrobials as first-line and alternative agents for treatment of patients with anthra

18 nsensus recommendations for first-choice and alternative agents for treatment.

19 Here, we explore the use of an alternative agent, galactose oxidase (GOase) isolated fr

20 ary fiber have been used as complementary or alternative agents in the management of manifestations o

21 lization and/or reduction in lesion size, 3) alternative agents not required due to VAN failure or to

22 ization and/or reduction in lesion size, (3) alternative agents not required due to VAN failure or to

23 o precise predictions about the influence of alternative agents of selection in the wild.

24 th 2.6% (22 of 851) in children treated with alternative agents (OR, 6.1 [95% CI, 1.9-16.7]).

25 Alternative agents should be considered for prophylaxis

26 Therefore, dose adjustment or use of alternative agents should be considered when strong P-gp

27 Other alternative agents should be considered.

28 High-dose propofol should be avoided and alternative agents should be instituted for sedation and

29 A screen of alternative agents showed that both an alternative EGFR

30 d heparin is most widely used anticoagulant, alternative agents such as bivalirudin have been used.

31 However, alternative agents such as fluoroquinolones and amoxicil

32 udy highlights the importance of identifying alternative agents such as vascular endothelial growth f

33 lantation, concerns about toxicity have made alternative agents, such as belatacept, attractive to cl

34 concentrations (>1 or 2 microg/mL); however, alternative agents, such as telavancin, daptomycin, line

35 We attempted to identify alternative agents that may target abnormalities within

36 nclude that EGCg may represent a natural and alternative agent to the antimicrobial chemicals current

37 use of valproic acid and its derivatives as alternative agents to address the neuropsychiatric sympt

38 tudies describing the physiologic effects of alternative agents to inhaled nitric oxide.

39 to patient intolerance or drug interactions, alternative agents to rifampin are needed for management

40 20-directed Abs currently being developed as alternative agents to rituximab in CLL based upon differ

41 triatum, as well as the clinical efficacy of alternative agents to vancomycin, particularly those sui

42 or whether a perioperative "bridge" with an alternative agent, typically a low-molecular-weight hepa

43 Exposure to LTG versus commonly prescribed alternative agents was the CTR.

44 which suggest consideration of the switch to alternative agents when the isolate has a high vancomyci

45 available treatments, as well as the use of alternative agents with a variety of targets, including